Evaluation of Gas 6 as a Prognostic Marker in Papillary Renal Cell Carcinoma

Introduction: Growth arrest-specific protein 6 (Gas 6) is a ligand that plays a role in proliferation and migration of cells. For several tumor entities, high levels of Gas 6 are associated with poorer survival. We examined the prognostic role of Gas 6 in renal cell carcinoma (RCC), especially in papillary RCC (pRCC), which is still unclear. Methods: The patients’ sample collection is a joint collaboration of the PANZAR consortium. Patients’ medical history and tumor specimens were collected from n = 240 and n = 128 patients with type 1 and 2 pRCC, respectively. Expression of Gas 6 was determined by immunohistochemistry. Results: In total, Gas 6 staining was evaluable in 180 of 240 type 1 and 110 of 128 type 2 pRCC cases. Kaplan-Meier analysis disclosed no significant difference in 5-year overall survival for all pRCC nor either subtype. Also, Gas+ and Gas– groups did not significantly differ in any tumor or patient characteristics. Conclusion: Gas 6 was not found to be an independent prognostic marker in pRCC. Future studies are warranted to determine if Gas 6 plays a role as prognostic marker or therapeutic target in pRCC.

[1]  M. Stöckle,et al.  Expression of nectin-4 in papillary renal cell carcinoma , 2022, Discover Oncology.

[2]  M. Rubin,et al.  The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. , 2022, European urology.

[3]  W. Weichert,et al.  Growth Arrest-Specific 6 in Chromophobe Renal Cell Carcinoma , 2022, Oncology.

[4]  C. Stief,et al.  The Prognostic Impact of PD-L2 in Papillary Renal-Cell Carcinoma , 2022, Urologia Internationalis.

[5]  M. Rubin,et al.  WHO 2022 landscape of papillary and chromophobe renal cell carcinoma , 2022, Histopathology.

[6]  M. Stöckle,et al.  The prognostic impact of Claudin 6 in papillary renal cell carcinoma. , 2022, Pathology, research and practice.

[7]  Donghua Zhang,et al.  Therapeutic inhibition of GAS6-AS1/YBX1/MYC axis suppresses cell propagation and disease progression of acute myeloid leukemia , 2021, Journal of Experimental & Clinical Cancer Research.

[8]  T. Tsunoda,et al.  Landscape of prognostic signatures and immunogenomics of the AXL/GAS6 axis in renal cell carcinoma , 2021, British Journal of Cancer.

[9]  D. Siemann,et al.  Therapeutic Targeting of the Gas6/Axl Signaling Pathway in Cancer , 2021, International journal of molecular sciences.

[10]  J. Cheville,et al.  New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia , 2021, Modern Pathology.

[11]  Minxiong Hu,et al.  The effect of the papillary renal cell carcinoma subtype on oncological outcomes , 2020, Scientific Reports.

[12]  P. Humphrey,et al.  High WHO/ISUP Grade and Unfavorable Architecture, Rather Than Typing of Papillary Renal Cell Carcinoma, May Be Associated With Worse Prognosis , 2020, The American journal of surgical pathology.

[13]  Yu‐quan Wei,et al.  AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications , 2019, Molecular Cancer.

[14]  Xin Zhou,et al.  Expression of CLDN6 in tissues of gastric cancer patients: Association with clinical pathology and prognosis , 2019, Oncology letters.

[15]  H. Höfler,et al.  High proliferation rate and TNM stage but not histomorphological subtype are independent prognostic markers for overall survival in papillary renal cell carcinoma. , 2019, Human pathology.

[16]  Zhiqiang Ma,et al.  Targeting Gas6/TAM in cancer cells and tumor microenvironment , 2018, Molecular Cancer.

[17]  H. Taubert,et al.  Differential prognostic value of MYC immunohistochemistry in subtypes of papillary renal cell carcinoma , 2017, Scientific Reports.

[18]  A. Hartmann,et al.  Differential prognostic value of MYC immunohistochemistry in subtypes of papillary renal cell carcinoma , 2017, Scientific Reports.

[19]  T. Powles,et al.  Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. , 2016, The Lancet. Oncology.

[20]  P. Humphrey,et al.  The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. , 2016, European urology.

[21]  Steven J. M. Jones,et al.  Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. , 2016, The New England journal of medicine.

[22]  R. Verhaak,et al.  Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma. , 2015, Cancer research.

[23]  Qiang Wang,et al.  Low claudin-6 expression correlates with poor prognosis in patients with non-small cell lung cancer , 2015, OncoTargets and therapy.

[24]  E. Rankin,et al.  Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET , 2014, Proceedings of the National Academy of Sciences.

[25]  Y. Doki,et al.  Prognostic Impact of Major Receptor Tyrosine Kinase Expression in Gastric Cancer , 2014, Annals of Surgical Oncology.

[26]  R. Birge,et al.  TAM receptors in apoptotic cell clearance, autoimmunity, and cancer , 2013, Autoimmunity.

[27]  D. Goldstein,et al.  Meta-Analysis of Microarray Data Identifies GAS6 Expression as an Independent Predictor of Poor Survival in Ovarian Cancer , 2013, BioMed research international.

[28]  Semi Kim,et al.  Gas6 induces cancer cell migration and epithelial-mesenchymal transition through upregulation of MAPK and Slug. , 2013, Biochemical and biophysical research communications.

[29]  D. Grueneberg,et al.  Evaluation of Tyro3 expression, Gas6-mediated Akt phosphorylation, and the impact of anti-Tyro3 antibodies in melanoma cell lines. , 2013, Biochemistry.

[30]  N. Rosenfeld,et al.  Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA , 2013, Nature.

[31]  J. Serth,et al.  Fibronectin 1 protein expression in clear cell renal cell carcinoma. , 2012, Oncology letters.

[32]  J. Serth,et al.  Caveolin 1 protein expression in renal cell carcinoma predicts survival , 2011, BMC urology.

[33]  Douglas B. Evans,et al.  Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma , 2011, Cancer.

[34]  J. Gerss,et al.  Prognostic factors of papillary renal cell carcinoma: results from a multi-institutional series after pathological review. , 2010, The Journal of urology.

[35]  B. Kleinschmidt-DeMasters,et al.  Claudin 6 Is a Positive Marker for Atypical Teratoid/Rhabdoid Tumors , 2010, Brain pathology.

[36]  B. Dahlbäck,et al.  Differential Expression of Axl and Gas6 in Renal Cell Carcinoma Reflecting Tumor Advancement and Survival , 2009, Clinical Cancer Research.

[37]  G. Feldmann,et al.  The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target , 2009, Cancer biology & therapy.

[38]  M. Kerin,et al.  Growth arrest-specific gene 6 expression in human breast cancer , 2008, British Journal of Cancer.

[39]  A. Ullrich,et al.  Axl and Growth Arrest–Specific Gene 6 Are Frequently Overexpressed in Human Gliomas and Predict Poor Prognosis in Patients with Glioblastoma Multiforme , 2008, Clinical Cancer Research.

[40]  L. Castello,et al.  Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor , 2005, Journal of cellular physiology.

[41]  H. Frierson,et al.  Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate , 1997, Cancer.

[42]  Abstr Act,et al.  Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma , 2016 .